黄土高原综合治理试验示范区航空遥感监测试验研究

本课题属“七·五”科技攻关项目《黄土高原综合治理》（75-04-03-15）研究内容之一。1、成功地进行了水土流失综合治理大范围（跨越了两个生物气候带，分布于5省区中的11个试验示范区）大比例尺彩红外航空遥感监测，提出了有关参数的选定原则。2、综合应用了目视判读、光学处理、机助分类与制图等遥感信息提取技术，初步形成了一套独具特色、且适用于地形复杂地区的遥感图象处理方法。3、首次设计和建立了以大比例尺信息源为基础、并直接为小流域综合治理服务的信息系统，共建立了76个原始数据库，采集了55bit属性数据，150兆图形和图象数据，编写了232个专业程序，170个说明、解释、提示文件。4、以遥感影像分析和综合治理信息系统为基础，建立了水土流失综合治理评级系统，首次设计和编制了《综合治理评价图》，即能定位、定量、形象地显示了小流域综合治理现状、又能表明进一步治理方向的重点和方向

激光离子源的首次在线实验结果

介绍了在线同位素分离器使用激光离子源的重要性、激光离子源原理和相关激光技术 ,以及热毛细管激光离子源和靶室的结构 .在首次在线实验中使用 50MeV u1 8O + natTa→1 67Yb(T1 2 =1 7.5m)反应道 ,实现了加速器、分离器和激光系统的联合运行 .通过测量分离后产物的γ谱 ,确定了分离后的 1 67Yb的产额 ,并与从产生截面、束流强度、收集时间和靶厚度计算得到的产生率相比 ,得到总分离效率约为 0 .2 % .通过有激光与无激光条件下测量的γ谱中 1 67Yb与 1 67Lu相应峰下面积比值K得到元素选择性η为 3 .2 .发现了新的 1 67Yb的长寿命高自旋的同质异能态 ,分析了提高效率的途径

Study on Fabrication and Characterization of Single CuO Nanowire Devices

uO nanowire is an important one-dimensional semiconductor nano-material which can be used in field effect transistors, photovoltaic cells, field emission nanodevices, and chemical and gas sensors. In this paper, CuO nanowires are synthesized by heating copper substrates in air, and the CuO nanowire is assembled on two opposite microelectrodes to fabricate a single CuO nanowire nanodevice by dielectrophoresis (DEP). In experiment, suitable parameters are chosen, such as concentration of the CuO nanowire solution, applied voltage and frequency on the microelectrodes, time of DEP duration, to assemble a single CuO nanowire on the microelectrode. Using this single nanowire nanodevice, this paper measured FET effect and photoconductivity of the single CuO nanowire. The results show that the single CuO nanowire nanodevice can work as a FET and it also has novel sensitivity to light intensity

双奇核~(170)Ta的转动带结构

用能量为105MeV 的~(16)O束流,通过~(159)Tb(~(16)O,5nγ)~(170)Ta 反应研究了~(170)Ta的高自旋态,观察到~(170)Ta 的3个转动带,其中一个耦合带和一个半退耦带中的非优先ΔI=2转动系列是由本工作发现的.文中还讨论了这些转动带可能的准粒子组态.High spin states in ~(170)Ta have been studied via ~(159)Tb (~(16)O,5nγ)~(170)Ta reaction at 105 MeV.Three rotational bands are observed,among which one coupled band and an unfavored ΔI=2 E2 squence are newly found in this work.The possible quasiparticle configurations of these bands are discussed.国家教委和国家自然科学基金资

大连极紫外相干光源

先进光源的发展在前沿科学研究中发挥的作用越来越重要。近十年来,飞速发展的自由电子激光技术为科学家们提供了探索未知世界、发现新科学规律和实现技术变革的重要工具。建成的大连极紫外(EUV)相干光源的运行波段为50~150nm,单脉冲能量大于100μJ,且可提供10-12 s和10-13 s量级的超快激光脉冲,是我国第一台自由电子激光用户装置,并且是国际上唯一运行在极紫外波段的自由电子激光用户装置,在世界范围内为用户提供具有高峰值亮度和超短脉冲的极紫外激光。大连EUV相干光源是由国家自然科学基金委资助、由中国科学院大连化学物理研究所和上海应用物理研究所共同承担的重大科学仪器研制项目,目标是打造一个以先进极紫外光源为核心、主要用于能源基础科学研究的光子科学平台

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials